ABSTRACT Background: A high dietary protein intake has been shown to blunt the deposition of intrahepatic lipids in high-fat-and high-carbohydrate-fed rodents and humans. Objective: The aim of this study was to evaluate the effect of essential amino acid supplementation on the increase in hepatic fat content induced by a high-fructose diet in healthy subjects. Design: Nine healthy male volunteers were studied on 3 occasions in a randomized, crossover design after 6 d of dietary intervention. 13 C]palmitate production. HFrAA significantly decreased IHCL compared with HFr (to 2.30 6 0.43 vol%; P , 0.05) but did not change VLDL-triglyceride concentrations or VLDL-[ 13 C]palmitate production. Conclusions: Supplementation with essential amino acids blunts the fructose-induced increase in IHCL but not hypertriglyceridemia. This is not because of inhibition of VLDL-[ 13 C]palmitate production. This trial was registered at www.clinicaltrials.gov as NCT01119989.
INTRODUCTION
A high fructose intake has been proposed as a major contributor to the recent increase in obesity prevalence (1) . Because obesity is frequently associated with insulin resistance and nonalcoholic fatty liver disease (NAFLD) 4 (2) , and intrahepatic fat may be tightly involved in hepatic insulin resistance (3), fructose-induced intrahepatic fat deposition may be a significant pathogenic mechanism. In both rodents (4) and humans (5) , high-fructose diets have been shown to increase intrahepatocellular lipids (IHCLs). Stimulation of hepatic de novo lipogenesis (DNL) may play a substantial role in this process (6, 7) .
Recent observations indicate that hepatic DNL and intrahepatic fat deposition may be modulated by dietary proteins. In rodents, increasing the dietary protein at the expense of carbohydrates reduced hepatic DNL (8) and hepatic steatosis (9, 10) . In healthy nonobese humans, protein supplementation reduced the accumulation of IHCL induced by a short-term high-fat diet, independently of changes in total fat and carbohydrate intakes (11) . In overweight subjects, whey protein supplementation for 4 wk significantly reduced IHCL (12) . There is therefore substantial evidence that a high protein intake may prevent NAFLD, even when energy intakes exceed energy requirements. The mechanisms underlying these effects of protein, however, remain poorly understood.
Recently, it was reported that supplementation with a mixture of essential amino acids (EAAs) reduced NAFLD in high-fat-fed rats (13, 14) , which suggests that the effects of a high protein intake may be mediated by specific amino acids. We therefore evaluated, in healthy humans, whether the increase in IHCL content induced by short-term fructose overfeeding could be prevented by a mixture of 5 essential amino acids. To better delineate the mode of action of EAA, we also measured whether EAAs altered VLDL-triglyceride production and fructose conversion into lipids after oral fructose loading.
SUBJECTS AND METHODS

Participants
Nine male volunteers with a mean (6SEM) age of 23.3 6 0.9 y were included in a randomized, crossover, single-blinded study. The subjects were healthy and nonobese [BMI (in kg/m 2 ): 22.6 6 0.5]. All subjects were nonsmokers, were sedentary, were not taking any medication, and had no history of diabetes. Before inclusion, they underwent a physical examination to ensure good physical health. The experimental protocol was approved by the Ethical Committee of Lausanne University School of Medicine. All participants provided written informed consent at the time of inclusion.
Study design
Each of the 9 volunteers was studied on 3 different occasions in a crossover design. On each occasion they received 1 of 3 different diets during a 6-d period and were asked to have minimal physical activity (,30 min/d walking, no sport activity) and not to consume alcohol or caffeine-containing beverages. The diets were administered in a randomized order and consisted of 1 of 3 diets:
1) Control, weight-maintenance diet with a total energy intake corresponding to 1.4 times resting energy requirements calculated by using the Harris-Benedict equation and containing 55% carbohydrate (of which 50% was starch and 5% was lactose and sucrose), 30% lipid, and 15% protein.
2)
Hypercaloric high-fructose + essential amino acid diet (HFrAA). This diet consisted of the control diet supplemented with 3 g fructose $ kg 21 $ d 21 , provided as drinks 5 times/d, plus 6.77 g of a mixture of EAAs (valine, isoleucine, leucine, lysine, and threonine) provided 3 times/d. EAAs were provided as a powder contained in sachets to be consumed mixed with yogurt; the EAA supplement was prepared by Ajinomoto Co Inc, and its safety for human use was verified according to standard methods. Its detailed composition is shown in Table 1 . Compliance was assessed by counting the empty, returned sachets.
3) Hypercaloric high-fructose diet + placebo (HFr), in which EAA supplements were replaced with placebo. This diet consisted of the control diet supplemented with 3 g fructose $ kg 21 $ d 21 and 2.2 g maltodextrin as a placebo 3 times/d; maltodextrin was provided as a powder contained in sachets to mix with yogurt to blind the study, but the amount of maltodextrin was minimized to avoid the potential contribution of maltodextrin to DNL.
Disregarding the supplements, all 3 diets provided the same amount of nonfructose carbohydrate, lipid, and protein, and HFr and HFrAA were both supplemented with identical amounts of fructose. HFr and HFrAA provided 136% and 138%, respectively, of the energy content of the control diet. A washout period of 4 to 10 wk was allowed between each diet.
The detailed compositions of the diets are shown in Table 2 . Subjects received their diet as prepackaged food items with instructions on how and when to consume them. Subjects were allowed to drink water and were instructed not to consume any other drink or food.
On the day 6 of each dietary condition, IHCL was measured by proton magnetic resonance spectroscopy ( 1 H-MRS). On day 7, the subjects were asked to come to the Centre of Clinical Research at 0700. The subjects were asked to void, they were weighed, and their body composition was measured by bioelectrical impedance (Imp DF50; ImdediMed). They were then asked to rest in a bed for the entire day. A catheter was inserted in a vein of the right arm, which was subsequently used for blood collections. A second catheter was inserted in a vein of the left arm, which was used for [ ] glycerol enrichment, lipid extraction was first performed by using chloroform and methanol. Triglyceride separation was assessed by solid-phase extraction column using chloroform. Methylation was accomplished by using methanolic 3N HCl followed by fatty acid methyl ester (FAME) extraction with hexane. Extracted glycerol was derivatized with acetic anhydride before analysis with GC-MS (15) .
After plasma deproteinization and partial purification over anion-and cation-exchange resins, [ 12 C ratio in the FAME derivatives was ascertained by using Delta Plus XP GCcombustion ratio MS (Thermo Electron Corporation). Tricosanoic acid methyl ester was used as an internal standard, and a quality-control sample (certified standard of eicosanoic acid FAME; Department of Geological Sciences, Indiana University) was run with each set of samples.
IHCL content was determined by 1 H-MRS on a clinical 3-tesla magnetic resonance system (Tim Trio; Siemens Medical) as previously described (12) . In brief, a volume of interest of 19 mL was localized in the liver evading large vessels and proximity to extrahepatic fat by using a double-echo localization sequence combined with Siemens prospective acquisition correction scheme (18) [magnetic resonance spectroscopy (MRS) echo time 30 ms, repetition time depending on breathing rate between 2.5 and 6 s]. MRS was preceded by fast-spin echo MRI in 3 planes by using the same prospective acquisition correction scheme triggering to visualize the liver and to reliably reproduce the placement of the region of interest in follow-up examinations. Reproducibility of repositioning was guaranteed by using screen shots of the prescribed region of interest in all 3 planes and was estimated to be well within a few millimeters in each direction. Magnetic resonace spectra were recorded with water presaturation to determine the lipid and metabolite spectra (32 scans, center frequency at 3 ppm) and without water suppression to acquire the water signal as internal standard (16 scans, center frequency at 4.7 ppm to guarantee the reference signal to originate from the same region as the main lipid signals). Automatic fitting of the MR spectra was performed with a Fitting Tool for Arrays of Interrelated Datasets (FiTAID: Inselspital) by using prior knowledge restraints (19) . The lipid spectrum was modeled with 9 Voigt lines. Absolute quantification was based on the peak areas of the main methylene proton peak, basic assumptions on lipid composition, an assumed liver water content, and relaxation corrections based on literature values (20) . The results are expressed as volume percentage of lipid. Reproducibility of IHCL measurement, expressed as CV, is estimated to be w10% (SD ,0.1% IHCL), similar to that determined with an earlier method at 1.5 tesla (21). Other groups have reported SDs of 0.6% IHCL (22) or a CV of ,10% (23).
Calculations
Glucose production was calculated from plasma [ 2 H 2 ]glucose enrichment by using Steele's equations for steady state conditions (24) . Gluconeogenesis was calculated from plasma [ 13 C]glucose enrichment and glucose production as described previously (25) . VLDL-triglyceride production was calculated as follow: a metabolic steady state existed with regard to VLDLtriglyceride kinetics, because plasma VLDL-triglyceride concentrations remained constant throughout the 9-h sampling period. The fractional turnover rate of VLDL-triglyceride was determined by using compartmental modeling analysis as previously described (26) . The rate of VLDL-triglyceride secretion was calculated by multiplying the fractional turnover rate of VLDL-triglyceride by the concentration of VLDL-triglyceride in plasma. The plasma clearance rate of VLDL-triglyceride was calculated by dividing the VLDL-triglyceride secretion rate by the VLDL-triglyceride concentration. The VLDL-[ were given every hour. For the HFrAA condition, EAA loads were given at 0 and 240 min (6.77 g EAA/load). Blood samples were drawn hourly and every 20 min over 1 h after glycerol injection. Indirect calorimetry was performed during the last 3 h of the test. EAA, essential amino acid; HFrAA, hypercaloric high-fructose + essential amino acid diet.
Statistical analysis
All values are expressed as means 6 SEMs. The normality of data and differences were checked with Shapiro-Wilk tests. Nonnormally distributed data (NEFA, glucagon, insulinemia, total triglyceride, IHCL, neoglucogenesis from fructose, VLDLtriglyceride secretion and clearance, and [ 13 C]palmitate production) were log transformed before statistical analysis). Fasting values and postfructose VLDL clearance and secretion were compared by paired t tests with Bonferroni correction. [ 13 C]Palmitate concentrations were not normally distributed, even after transformation, and were compared by using Wilcoxon's signed-rank test.
All variables measured at different time points after fructose loading were reduced to a single value by calculating their AUCs. Energy expenditure, substrate oxidation, endogenous glucose production, gluconeogenesis from fructose, fructose oxidation, total triglyceride, and VLDL-triglyceride were also averaged over the last hour of the fructose-loading test when steady state was attained. AUCs and averaged values over the last hour were then analyzed by paired t tests with Bonferroni correction. A difference was considered significant when the P value was ,0.05. All statistical analyses were performed by using STATA version 10 (Stata Corp).
RESULTS
Anthropometric variables, IHCL, and fasting variables
No difference in body weight or body fat content was detected between the 3 different dietary conditions ( Table 3 ). Blood pressure was also not statistically different: systolic blood pressure (control diet, 120 6 2; HFr, 120 6 2; HFrAA, 121 6 4 mm Hg; NS) and diastolic blood pressure (control diet, 67 6 1; HFr, 66 6 2; HFrAA, 68 6 2 mm Hg; NS). Both HFr and HFrAA treatments increased the IHCL content when compared with the control diet (P , 0.05). However, IHCL was 16.1% lower with HFrAA than with HFr (P , 0.05; Table 3 ).
Both HFr and HFrAA decreased fasting NEFA concentrations and increased fasting triglyceride, VLDL-triglyceride, and lactate concentrations when compared with the control diet (P , 0.05). In addition, fasting insulinemia was greater with HFr than with the control diet (P , 0.05). The other measured variables showed no significant differences (Table 3) .
Hormone and substrate concentrations, energy expenditure, and substrate oxidation during oral fructose loading During the 9 h after fructose loading, AUCs for glycemia and glucagonemia were not statistically significantly different. Insulinemia was greater with both HFr and HFrAA than with the control diet (P , 0.01), whereas the NEFA concentration was lower with HFrAA than with the control diet (P , 0.05) (Figure 2) .
Energy expenditure did not differ significantly between conditions, but carbohydrate oxidation was significantly greater with HFr than with the control diet (P = 0.035); we did not detect any difference between HFr and HFrAA, however. No significant differences in lipid oxidation were found between treatments ( Figure 3 ).
Glucose production, gluconeogenesis from fructose, and fructose oxidation during oral fructose loading Basal breath CO 2 (1.083 6 0.001, 1.083 6 0.001, and 1.083 6 0.001 atom% 13 C) and VLDL-[ C) were not statistically different between dietary conditions, which indicated no carryover effect of previous tracer infusions. During the fructose-loading tests, near steady state conditions were obtained during the period covering 480-540 min in all conditions. Over the last hour of the test, neither glucose production nor gluconeogenesis differed between treatments. Fructose oxidation was greater with HFr than with the control diet (P , 0.05) ( Table 4) .
Plasma triglyceride, VLDL, and VLDL production during oral fructose loading
Mean triglyceride and VLDL-triglyceride over the last hour of the test were significantly higher with both HFr and HFrAA than with the control diet (P , 0.05) but did not differ between HFr and HFrAA ( Figure 4) . The VLDL-triglyceride fractional turnover rate was significantly lower with HFr and HFrAA treatments than with the control diet (P , 0.01). VLDL-triglyceride secretion was significantly greater with HFrAA than with the control diet (P , 0.5), whereas VLDL-triglyceride clearance was lower with both HFr and HFrAA treatments than with the control diet (P , 0.05) ( Table 4) . All values are means 6 SEMs; n = 9 subjects. Effects of the dietary interventions on anthropometric and metabolic variables were evaluated with paired t tests followed by Bonferroni correction. Means with different superscript letters are significantly different, P # 0.05 (Bonferroni-corrected). HFr, hypercaloric high-fructose + placebo diet; HFrAA, hypercaloric highfructose + essential amino acid diet; IHCL, intrahepatocellular lipid; NEFA, nonesterified fatty acid; TG, triglyceride.
2 Log transformed before the statistical analysis. 
DISCUSSION
In the current study we evaluated whether the effects of fructose overfeeding could be prevented by supplementation with EAA. The mixture of amino acids used was based on previous animal studies, which showed a reversal of high-fat-diet-induced hepatic steatosis in rodents (13) . Because this was a "proof of concept" type of study, we deliberately selected relatively high daily doses of EAAs.
Consistent with our previous observations, short-term fructose overfeeding with placebo led to a significant increase in VLDLtriglyceride and total triglyceride concentrations and to a .2-fold increase in IHCL content (5, 7) . In previous studies, we observed that fructose overfeeding increases fasting hepatic DNL and endogenous glucose production (5, 7). In the current study, we further extended these observations by showing that fructose overfeeding also enhances hepatic VLDL-triglyceride [ 13 C] palmitate production after oral loading with [
13 C]labeled fructose, which indicates that fructose conversion into fat is enhanced with chronic fructose ingestion. In addition, fructose overfeeding insignificantly increased VLDL-triglyceride secretion but significantly decreased VLDL-triglyceride clearance. Such inhibition of triglyceride-rich lipoprotein clearance was previously reported after acute fructose ingestion (26) or, more generally, with high-carbohydrate diets (27) and makes a major contribution in the pathogenesis of hypertriglyceridemia.
When fructose overfeeding was associated with supplementation of 20 g EAA/d, there was a significant reduction in IHCL accumulation. This effect of EAA is consistent with that of previous reports showing that dietary protein can reduce the increase in IHCL induced by short-term fat overfeeding (11) and partially revert hepatic steatosis in overweight female patients (12) . It suggests that this effect may be mediated by the effect of one or several of the EAAs included in the supplement used. . Fructose loads were ingested hourly from 0 to 480 min. Under the HFrAA condition, essential amino acid loads were given at 0 and 240 min. AUCs for glycemia (B), glucagonemia (D), insulinemia (F), and NEFA concentrations (H) were compared by paired t tests with Bonferroni correction. Glucagonemia, insulinemia, and NEFAs were log transformed before statistical analysis. Means with different superscript letters are significantly different, P , 0.05 (Bonferroni-corrected). C, control; HFr, hypercaloric high-fructose + placebo diet; HFrAA, hypercaloric high-fructose + essential amino acid diet; NEFA, nonesterified fatty acid.
Our current results cannot accurately identify how the EAAs reduced IHCL. After fructose overfeeding, stimulation of hepatic DNL may play an important role in increasing IHCL. In this study, hepatic conversion of [ 13 C]fructose into lipids was semiquantitatively evaluated by monitoring VLDL-[ 13 C]palmitate production. We observed that it was unchanged by EAA supplementation; hence, it appears unlikely that EAAs primarily inhibited de novo fatty acid synthesis in the liver. However, this measurement evaluated only the contribution of DNL to the pool of lipids secreted by the liver as VLDL-triglyceride, and we FIGURE 3. Mean (6SEM) time course of energy expenditure (A), carbohydrate oxidation (C), and lipid oxidation (E) over the last 3 h of fructose loading and corresponding AUCs for the last 3 h of the test (B, D, and F) (n = 9). Fructose loads were ingested hourly from 0 to 480 min. Under the HFrAA condition, essential amino acid loads were given at 0 and 240 min. AUCs were compared by paired t tests with Bonferroni correction. Means with different superscript letters are significantly different, P , 0.05 (Bonferroni-corrected). C, control; HFr, hypercaloric high-fructose + placebo diet; HFrAA, hypercaloric highfructose + essential amino acid diet.
TABLE 4
Glucose production, fructose oxidation, and average total triglyceride and VLDL-triglyceride over the last hour of the test; VLDL kinetics; and [ 1 All values are means 6 SEMs; n = 9 subjects. Paired t tests and Bonferroni correction were used for the statistical evaluation. Means with different superscript letters are significantly different, P # 0.05 (Bonferroni-corrected). All variables were log transformed before statistical analysis. EGP, endogenous glucose production; FTR, fractional turnover rate; HFr, hypercaloric high-fructose + placebo diet; HFrAA, hypercaloric high-fructose + essential amino acid diet; TG, triglyceride.
cannot exclude that the contribution of DNL to IHCL synthesis was inhibited. In contrast, we observed that EAAs increased VLDL-triglyceride secretion, which was significantly greater than in the control condition. It is therefore possible that EAAs favored the release of newly synthesized fatty acids as VLDLtriglyceride, thus reducing IHCL storage. Such a mechanism is consistent with our recent observation that co-ingestion of protein and fructose enhanced postprandial triglyceride responses in healthy volunteers (28) . In the current study, however, an increase in plasma triglyceride concentrations was prevented by a simultaneous increase in VLDL-triglyceride clearance induced by EAAs.
It may also have been hypothesized that EAAs diverted fructose away from DNL and lipid storage by enhancing other quantitatively major pathways of fructose disposal, ie, gluconeogenesis and fructose oxidation. Our current results, however, fail to support such an explanation. Gluconeogenesis from fructose was identical with and without EAAs. 13 CO 2 production, which provides an estimate of total fructose [ie, direct or indirect through oxidation of glucose and lactate synthesized from fructose (29) ] was also unaltered. Finally, we also considered the possibility that EAAs reduce IHCL by enhancing whole-body or hepatic lipid oxidation. Our current results, however, do not support this hypothesis, because EAAs did not stimulate total energy expenditure or net lipid oxidation and did not increase plasma b-hydroxybutyrate concentrations. The latter measurement only represents indirect estimation of hepatic ketogenesis and b-oxidation, however.
On the basis of these negative observations, we conclude that EAA supplementation improved hepatic fat content through mechanisms not specifically evaluated in our experiment. It is possible that EAAs exerted direct regulatory effects on hepatic lipid metabolism through one or several amino acids, which directly activated key intrahepatic regulatory factors. Thus, leucine is known to activate mammalian target of rapamycin, a regulatory factor that, when stimulated, generally causes insulin resistance (30) . Inhibition of this protein by rapamycin is, however, known to be associated with increased VLDL-triglyceride secretion and dyslipidemia, which are alterations commonly observed in insulin resistance (31) . This suggests that leucine may have dual effects on hepatic intermediary metabolism, ie, increased triglyceridemia secondary to insulin resistance and decreased hepatic VLDL-triglyceride secretion. In support of possible beneficial effects of leucine on hepatic steatosis, it was recently reported that increased dietary leucine improved insulin sensitivity and hepatic steatosis in high-fat-fed mice (32) . The mediator involved in these effects of leucine, however, remains to be identified. Furthermore, whether the other EAAs present in our supplement exerted similar effects remains to be determined. This further supports the hypothesis that leucine may have complex, yet incompletely understood, effects on intracellular signaling pathways.
Our study had some limitations that need to be pointed out. First, the incorporation of 13 C administered as [ 13 C 6 ]fructose into VLDL-palmitate was used as an index of hepatic DNL from fructose. This is a semiquantitative method, which does not allow an accurate assessment of fatty acid synthesis because of the fact that the isotopic enrichment of intrahepatic acetyl-CoA, the actual precursor for fatty acid synthesis, could not be measured in these experiments. Second, this method provides an estimate of the contribution of fructose-induced hepatic DNL to VLDL-palmitate secretion. However, newly synthesized intrahepatic palmitate partitions between VLDLtriglyceride secretion and intrahepatic triglyceride storage, and we cannot directly assess the effect of EAAs on the latter pathway. Third, hepatic lipid oxidation, which was a potential target of EAAs, was not directly measured but was assessed by monitoring the plasma concentration of b-hydroxybutyrate. This was, however, done under somewhat drastic fructose uptakes, ie, after fructose loading. Because fructose potently inhibits hepatic lipid oxidation, b-hydroxybutyrate concentrations were suppressed to almost undetectable concentrations in all 3 conditions tested, and it is possible that this precluded detection of a stimulation by EAAs. Fourth, although fructose overfeeding reproduces to some extent some of the features of the metabolic syndrome, the pathogenesis of the metabolic syndrome in obese patients is likely to be substantially different, with contributions of both carbohydrate and fat overfeeding and of an enhanced flux of endogenous NEFAs (15) . Further studies will therefore be required to evaluate whether EAAs can efficiently reduce IHCL in obese patients with the metabolic syndrome. Fifth, the current design strongly suggests that at least part of the effects of high-protein diets on intrahepatic lipid metabolism is mediated by one or several of the EAAs present in our supplement. The current design, however, did not allow us to identify which amino acid is involved. Finally, a relatively large dose of daily EAAs was selected for this initial, proof-of-concept study, and further studies will be required to assess the effects of smaller EAA doses.
In summary, our results indicate that supplementation with EAAs blunts the accumulation of intrahepatic fat in response to high fructose but not hypertriglyceridemia. That suggests that the improvement in intrahepatic fat observed in previous, high-fat high proteins (8-10) was mediated by one or several of these EAAs provided as supplements.
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